Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Steve Harmon who wrote (1008)	1/19/1998 5:37:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 2742

Galton and BlueStone: Yet another piece of science for you to ignore. Stanford (pronounced Stan..... Ford, as in the name and the car). This is an academic institution. They have telephones. They have a licensing group. This licensing group has used the telephone in the past to communicate with a company called Vical (pronounced Vi..... Cal, as in the name and the name). If you read through this thread, you will understand the nature of those past telephone (pronounced Tell....Uh......Fone) conversations. Before the lethargy set in, you did a deal with a company known as GTI. They have TellUhFones too. UI - 98031284 AU - Maecker HT AU - Umetsu DT AU - DeKruyff RH AU - Levy S TI - DNA vaccination with cytokine fusion constructs biases the immune response to ovalbumin. AB - DNA vaccination may work through direct transfection of antigen presenting cells (APC), or by secretion of the encoded protein by muscle or skin cells for uptake by APC. If cytokines are attached to the antigen, they may influence APC or responding T cells to drive the response toward a Th1 or Th2 direction, and/or potentiate it in an antigen-specific manner. To test this concept, expression vectors were constructed containing the ovalbumin (OVA) gene either alone, or linked to cytokine genes including GM-CSF, IFN-gamma, IL-2, IL-4, IL-12, or a sequence encoding nine amino acids of IL-1 beta. These constructs expressed OVA-cytokine fusion proteins in vitro which retained cytokine bioactivity. C57BL/6 mice were injected intramuscularly with the DNA constructs. Little if any OVA-specific antibody was produced in response to any of the DNA constructs, except for OVA-IL-4. However, lymphocytes from BALB/c mice vaccinated with OVA-IL-12 and OVA-IL-1 beta constructs produced more IFN-gamma and less IL-4 during in vitro restimulation assays than did other groups. All constructs elicited OVA- specific cytotoxic responses which were maintained or even increased over 16 weeks. The OVA-IL-12 and OVA-IL-1 beta peptide constructs elicited the strongest cytotoxic responses at 2 weeks postinjection. Cytotoxic responses were seen in all animals, even those lacking OVA- specific Ab, and were not related to Ab level. These studies indicate that the humoral, cytokine, and cytotoxic responses to DNA vaccination can be effectively altered by certain cytokine fusion constructs. AD - Department of Medicine/Oncology, Stanford University Medical Center, CA 94305, USA. SO - Vaccine 1997 Oct;15(15):1687-96